These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38794946)

  • 1. A retrospective review of rasburicase utilization in pediatric and adult patients across a large health system.
    Kamel A; Sanders M; Dyk H; Hamilton T
    J Oncol Pharm Pract; 2024 May; ():10781552241253214. PubMed ID: 38794946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
    Savva DA; Herrera N; Rohatgi R
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27236. PubMed ID: 29905398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of rasburicase utilization for tumor lysis syndrome management in pediatric and adult patients in the inpatient and outpatient settings.
    Abousaud MI; Rush MC; Rockey M
    J Oncol Pharm Pract; 2021 Jul; 27(5):1165-1171. PubMed ID: 32727320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
    Vines AN; Shanholtz CB; Thompson JL
    Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
    McBride A; Lathon SC; Boehmer L; Augustin KM; Butler SK; Westervelt P
    Pharmacotherapy; 2013 Mar; 33(3):295-303. PubMed ID: 23456733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
    McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD
    Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome.
    Boutin A; Blackman A; O'Sullivan DM; Forcello N
    J Oncol Pharm Pract; 2019 Apr; 25(3):577-583. PubMed ID: 29320954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
    Herrington JD; Dinh BC
    J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
    Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS
    J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome.
    Philips A; Radhakrishnan V; Ganesan P; Ganesan TS; Ramamurthy J; Dhanushkodi M; Sagar TG
    Indian J Hematol Blood Transfus; 2018 Oct; 34(4):618-622. PubMed ID: 30369730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
    Patel KS; Lau JE; Zembillas AS; Gallagher EM
    J Oncol Pharm Pract; 2017 Jul; 23(5):333-337. PubMed ID: 27084514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
    Knoebel RW; Lo M; Crank CW
    J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective observational study of a low fixed-dose rasburicase protocol for the treatment of tumor lysis syndrome in adults.
    Hossain S; Naber M; Yacobucci MJ
    J Oncol Pharm Pract; 2022 Sep; 28(6):1326-1331. PubMed ID: 34115548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.
    Eng S; Lee CS; Ahn S; Sharma A
    J Oncol Pharm Pract; 2020 Mar; 26(2):338-344. PubMed ID: 31088218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
    Cortes J; Moore JO; Maziarz RT; Wetzler M; Craig M; Matous J; Luger S; Dey BR; Schiller GJ; Pham D; Abboud CN; Krishnamurthy M; Brown A; Laadem A; Seiter K
    J Clin Oncol; 2010 Sep; 28(27):4207-13. PubMed ID: 20713865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
    Gupta G; Seth T; Garg V; Juneja R; Mahapatra M; Datta SK; Upadhyay AD; Saxena R
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e99-e104. PubMed ID: 33039358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review.
    Chiang J; Chan A; Lian T; Tay K; Quek R; Tao M; Lim ST
    Asia Pac J Clin Oncol; 2011 Dec; 7(4):351-6. PubMed ID: 22151984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
    Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
    Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
    Cairo MS; Thompson S; Tangirala K; Eaddy MT
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):173-178. PubMed ID: 27965022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
    Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
    Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.